Michael A. Werner, MD, FACS

Dr. Werner is a board-certified urologist who received his specialized fellowship training in male infertility and surgery, and male sexual dysfunction at Boston University Medical Center. Dr. Werner completed his urology residency at Mount Sinai Medical Center in Manhattan and received his medical school training at the University of California at San Francisco. He holds an undergraduate degree in Biology from Harvard College.

Dr. Werner’s private practice is limited to male infertility and male sexual dysfunction. He lectures and writes extensively on these topics in medical journals and books. More importantly, his concentration in these areas means he practices the latest and most advanced treatments and surgical techniques, ensuring the greatest likelihood of success for his patients.

“You don’t have to suffer with ED if you deal with a specialist in the field; not strictly a urologist, but someone who’s trained and practiced for years in this area. Dr. Werner was a totally upbeat guy and easy to talk to. He was that specialist for me.”
— Jim, February 2010

As the Medical Director of Maze Sexual & Reproductive Health, Dr. Werner diagnoses and treats erectile dysfunction, premature ejaculation, impotence, andropause, and the many causes of male infertility. The practice is founded on the belief that patients should have a complete understanding of the medical options available to them, and that the patient and physician should decide, together, on the course of treatment that makes the most medical and personal sense.

Curriculum Vitae
Professional Activity
1994-Present Private Practice
Practice limited to Sexual Dysfunction, Male Infertility, Microsurgery
Offices in Manhattan and Westchester, New York, and Norwalk, Connecticut
 1997-Present Medical Director
Maze Laboratories
Westchester
 2000-Present Medical Director
Maze Women’s Sexual Health
Offices in Manhattan, Long Island and Westchester, New York
Education
1993-1994 Boston University Medical Center, Boston, Massachusetts
Fellow in male infertility and erectile dysfunction with Robert D. Oates, M.D. and Irwin Goldstein M.D.
1989-1993 Mount Sinai Medical Center, New York, NY
Urology resident
1987-1989 Beth Israel Medical Center, New York, NY
Second and third year surgical resident
1986-1987 St. Luke’s Hospital, New York, NY
Medical internship
1986 University of California, San Francisco Medical School
Doctor of Medicine
1984-1985 The Jewish Theological Seminary, New York, NY 
Coursework towards a Masters in Hebrew Letters
1981 Harvard College, Cambridge, MA
B.A. in Biology, Cum Laude. Received the John Harvard and Detur Awards for academic achievement.
Hospital Affiliations
White Plains Hospital White Plains, New York
Westchester County Medical Center  Valhalla, New York
Montefiore Medical Center  Bronx, New York
New York Medical Center  New York, New York

Associations

Society for the Study of Impotence

Society for the Study of Male Reproduction

American Urological Association

The American Society for Reproductive Medicine

Impotence World Association

American Society of Andrology

American Board of Bioanalysts

American Board of Urology

Society of Urologic Prosthetic Surgeons

Research Studies
12/10-1/12 Repros Therapeutics, Inc. | Investigator
A randomized, parallel, double-blind, placebo-controlled exploratory study to evaluate the efficacy of androxal® in improving glycemic control in men with secondary hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and type 2 diabetes mellitus with sub-optimum treatment. Protocol Number ZA-202
2/11-1/12 Repros Therapeutics, Inc. | Investigator
A randomized, double-blind, placebo-controlled, parallel, multi-center Phase IIb study to evaluate normalization of morning testosterone levels in men with secondary hypogonadism with confirmed morning testosterone levels Protocol Number ZA-203

7/10-4/11

Allergen | Investigator, Phase III
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the safety and efficacy of a single treatment of BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex followed by a treatment with BOTOX® as applicable in patients with idiopathic overactive bladder with urinary incontinence. Protocol Number 191622-095-01
5/09-8/09 Johnson & Johnson | Investigator
In vitro study on the effects of vaginal lubricant prototypes when mixed with human semen samples on sperm motility. Protocol Number KOYNAP00 06
1/08-8/09 Graceway Pharmaceuticals | Investigator
A Phase 3, randomized, double-blind, placebo-controlled, mulit-center, efficacy and safety study of imiquimod creams in the treatment of external genital warts. Protocol Number GW01-0801
8/07-8/09 QuatRx Pharmaceuticals | Primary Investigator
Efficacy and safety of Ospemifene in the treatment of moderate to severe vaginal dryness and vaginal pain associated with sexual activity, symptoms of Vulvar and Vaginal Atrophy (VVA), associated with menopause: A 12-week, randomized, double-blind, placebo-controlled, parallel-group study comparing oral Ospemifene 60 mg daily dose with placebo in postmenopausal women. Protocol Number ZA-203
3/08-8/09 Auxilium Pharmaceutics, Inc. – Hypogonadiasm | Primary Investigator
Observational study to evaluate the effectiveness of Testim 1% in a large sample of hypogonadal men from a variety of “real world” clinical practice settings by assessing sexual function, mood (depression), body mass index, and testosterone levels. Protocol Number 15-50821
6/08-8/09 Repros Therapeutics, Inc. – Secondary Hypogonadism | Primary Investigator
A Randomized, open-label, fixed dose, active-control, multi-center Phase IIB study to evaluate fertility in men with secondary hypogonadism comparing topical exogenous administration of testosterone and Androxal (Enclomiphene). Protocol Number ZA-201
5/08-Present Biosante Pharmaceuticals – Hypoactive Sexual Desire Disorder | Primary Investigator
A Phase III, randomized, double-blind, placebo-controlled, multi-center study of long-term safety and efficacy of LibiGel for the treatment of hypoactive sexual desire disorder in postmenopausal women. Protocol Number TEST WOO7
5/08-Present Biosante Pharmaceuticals – Hypoactive Sexual Desire Disorder | Primary Investigator
A Phase III, randomized, double blind, placebo controlled, multi center study of hypoactive sexual desire disorder in surgically menopausal women. Protocol Number TEST WOO
1/07-10/08 Medicis Pharmaceutical Corporation – Spermatogenesis | Primary Investigator
Randomized, double-blind, placebo-controlled study to examine the effects of Minocycline Extended-Release tablets on spermatogenesis in human males. Protocol Number MP-0104-18
2/07-8/08 Bristol-Myers Squibb Company – Spermatogenesis | Primary Investigator
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate spermatogenesis in healthy male subjects during administration of BMS-562086. Protocol Number CN148-014-017
8/06-8/08 Palatin Technologies, Inc. – Female Sexual Dysfunction | Primary Investigator
A placebo-controlled, randomized, double-blind, parallel group, at-home exploratory study to evaluate the efficacy and safety ofintranasally administered PT-141 in subjects with female sexual arousal disorder. Protocol Number PT-141-2005-53FB
7/06-9/08 Boehringer Ingelheim Pharmaceuticals, Inc. – Female Sexual Dysfunction| Primary Investigator
A 24 week, randomized, double-blind, placebo-controlled, safety and efficacy  trial of Flibanserin 25 milligrams twice daily and 50 milligrams once and twice daily in premenopausal women with hypoactive sexual desire disorder in North America. Protocol Number 511.70
10/02-12/03 Pfizer, Inc. – Sexual Dysfunction, Study #1082
A randomized, double-blind, placebo-controlled, fixed dose, multi-center study to evaluate the efficacy, safety and toleration of oral Sildenafil administered for 12 weeks to post menopausal women who have been diagnosed with female sexual arousal disorder.
10/02-12/03  Pfizer, Inc. – Sexual Dysfunction, Study #1123
A randomized, double-blind, double dummy, placebo-controlled, fixed dose, multi-center study to evaluate the efficacy, safety and toleration of oral Sildenafil citrate administered for 12 weeks to pre-menopausal women who have been diagnosed with female sexual arousal disorder.
7/03-2/04  Pfizer, Inc. – Sexual Dysfunction, Study #1133
An open-label, multi-center extension study to evaluate the safety, toleration and the sustained efficacy of oral Sildenafil administered to women who have been diagnosed with female sexual arousal disorder.
10/03-6/04  Pfizer, Inc. – Sexual Dysfunction, Study #1179
A multi-center open label flexible dose study to investigate the use patterns of Viagra  and the ability of investigators to further optimize subject satisfaction with Viagra through customized instruction.
11/03-1/04 Bayer Pharmaceutical Corp. – Male Sexual Dysfunction, Study #100477 Version 19
REALISE – Real Life Safety and Efficacy – A post-marketing (Phase IV) surveillance study of Levitra. Protocol Number ZA-203
Publications

Goldstein, I., Nehra, A., Werner, M., Geffin, M., Korn, K., Krane, R.
Technique and follow-up of sharp corporal tissue excision procedure for prosthesis implantation with bilateral severe diffuse corporal fibrosis. Journal of Urology 1995; 4 (program Supplement); 360A. Abstract.

Goldstein, I., Nehra, A., Werner, M., Geffin, M., Korn, K., Krane, R.
Technique and follow-up of sharp corporal tissue excision procedure for prosthesis implantation with bilateral severe diffuse corporal fibrosis. International Journal of Impotence Research, Sept. 6(1), Abstract A58, September, 1994.

Goldstein, I., Nehra, A., Werner, M., Geffin, M., Korn, K., Krane, R.
Technique and follow-up of sharp corporal tissue excision procedure for prosthesis implantation with severe diffuse corporal fibrosis. Journal of Urology 1995; 4 (program Supplement); 44A. Video.

Goldstein, I., Nehra, A., Werner, M., Geffin, M., Korn, K., Krane, R.
Technique and follow-up of sharp corporal tissue excision procedure for prosthesis implantation with bilateral severe diffuse corporal fibrosis. Journal of Urology 153(4). Abstract #V-17, April, 1995.

Goldstein, I., Geffin, M., Werner, M.A., Nehra, A
Technique and Follow-up of sharp corporal tissue excision procedure for prosthesis implantation with bilateral severe diffuse corporal fibrosis. Abstract No. 7, 63rd Annual New England Section, American Urological Association, Bermuda, September 29, 1994.

Gordon, J.W., Werner, M., Champlin, A., Schroeder, A., Mobraaten, L.
Development of a fertilization microchamber that spontaneously concentrates motile sperm around oocytes and improves in vitro fertilization. Fertility and Sterility 1991; 56 (program Supplement): 567-568. Abstract.

Nehra, A., Werner, M.A., Goldstein, I.
Reconstructive Penile Surgery. In: Pediatric and Adult Reconstructive Urologic Surgery. Edited by Libertino, JA. Baltimore: Williams and Wilkins. In press.

Nehra, A., Werner, M.A., Title, C.I., Bastuba, M., Oates, R.D.
Vibratory stimulation and electroejaculation as therapy for spinal chord injured patients: semen parameters and pregnancy rates. Fertility and Sterility 1994; 62 (Program Supplement): S59. Abstract

Nehra, A., Werner, M.A., Title, C.I., Bastuba, M., Oates, R.D.
Vibratory stimulation and electroejaculation as therapy for spinal chord injured patients: semen parameters and pregnancy rates. Journal of Urology 155(2): 554-559, February, 1996.

Nehra, A., Werner, M.A., Krane, R. J., Goldstein, I
High resolution ultrasonography of the penis: a non-color duplex scanner with a 13.5 MHz pulsed wave probe (Proscan Excel). International Journal of Impotence Research, 6(1), Abstract D58, September, 1994.

Nehra, A., Werner, M.A., Title, C., Oates, R.D
Semen parameters and pregnancy rates in an ejaculatory spinal cord injured patients treated with vibratory stimulation and electroejaculation. Abstract No. 12, 63rd Annual New England Section, American Urological Association, Bermuda, September 29, 1994.

Nehra, A., Werner, M.A., Title, C., Oates, R.D.
Semen parameters and pregnancy rates in an ejaculatory spinal cord injured patients treated with vibratory stimulation and electroejaculation. Fertility and Sterility 62(suppl) Abstract#0-126, November, 1994.

Werner, M.A., Barnhard, J., Gordon, J.W.
The effects of aging on sperm and oocytes. Seminars in Reproductive Endocrinology 1991; 9: 231-240.

Werner, M.A., Lipshultz, L.I.
The new technology in male infertility: Is it practical? Contemporary Urology 1992; 4: 29-38.

Werner, M.A., Nehra, A., Goldstein, I.
Duplex ultrasonography: the advantages of a 13.5 MHz probe (Proscan Excel). International Symposium of Impotence Research. In press.

Werner, M.A., Oates, R.D.
Male Infertility. In: Primary Care and General Medicine. Edited by Noble, J. St. Louis: Mosby-Year Book, 1996. 1764-1772.

Werner, M.A., Goldstein, I., Krane, R.J.
Male Sexual Dysfunction. In: Primary Care and General Medicine. Edited by Noble, J. St. Louis: Mosby-Year Book, 1996, 1797-1803.